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BACKGROUND: AKT, a critical effector of the phosphoinositide 3-kinase (PI3K) signalling cascade, is an intensely pursued
therapeutic target in oncology. Two distinct classes of AKT inhibitors have been in clinical development, ATP-competitive and
allosteric. Class-specific differences in drug activity are likely the result of differential structural and conformational requirements
governing efficient target binding, which ultimately determine isoform-specific potency, selectivity profiles and activity against
clinically relevant AKT mutant variants.
METHODS: We have carried out a systematic evaluation of clinical AKT inhibitors using in vitro pharmacology, molecular profiling
and biochemical assays together with structural modelling to better understand the context of drug-specific and drug-class-specific
cell-killing activity.
RESULTS: Our data demonstrate clear differences between ATP-competitive and allosteric AKT inhibitors, including differential
effects on non-catalytic activity as measured by a novel functional readout. Surprisingly, we found that some mutations can cause
drug resistance in an isoform-selective manner despite high structural conservation across AKT isoforms. Finally, we have derived
drug-class-specific phosphoproteomic signatures and used them to identify effective drug combinations.
CONCLUSIONS: These findings illustrate the utility of individual AKT inhibitors, both as drugs and as chemical probes, and the
benefit of AKT inhibitor pharmacological diversity in providing a repertoire of context-specific therapeutic options.
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BACKGROUND
The serine/threonine kinase AKT is a critical effector of the
phosphoinositide 3-kinase (PI3K) signalling pathway and regulates
a number of oncogenic functions, including cell survival.1 It is
aberrantly activated in a wide range of human tumours, and
consequently, it has been actively pursued as a therapeutic
target.1,2 Although pharmacological inactivation of AKT has been
shown to have broad anti-tumour activity in a number of PI3K-
active pre-clinical models,3 the clinical activity of AKT inhibitors as
single agents has been primarily limited to tumours with a rare
AKT-activating hot-spot mutation. This is clearly illustrated by data
from two independent basket studies of the AKT inhibitor
capivasertib (also called AZD5363),4,5 which have shown signifi-
cant response rates in patients whose tumours carried the AKT1
E17K mutation.
Two distinct classes of AKT inhibitors are currently in clinical
development, ATP-competitive and allosteric. Interestingly, in
contrast to capivasertib, an ATP-competitive inhibitor, the
allosteric AKT inhibitor MK-2206, has failed to show single-agent
activity in a number of clinical trials,6 while another allosteric
inhibitor called miransertib (also called ARQ 092) has shown
promising results in early phase studies, including in a patient with
an E17K mutation.7 It has been previously shown that the half-
maximal inhibitory concentration (IC50) for the allosteric tool
compound AKT1/2 inhibitor VIII is approximately 5-fold higher in
AKT1 E17K compared to the wild-type enzyme while having no
effect on the IC50 for an ATP-competitive inhibitor.
8 Similarly, it has
been shown in isogenic cell line models that the IC50 for
capivasertib was unaffected by the E17K mutation, while that of
MK-2206 was right-shifted.9 These observations are consistent
with the reported differences in clinical activity between
capivasertib and MK-2206, but raise interesting questions about
the mechanistic basis for the observed activity of other allosteric
inhibitors such as miransertib.7,10,11 The reasons for these varying
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outcomes and for the disappointing clinical activity of various AKT
inhibitors in other tumours with hyperactive (but wild-type) AKT
are therefore not entirely clear. However, given that AKT inhibitors
can differ not only in their pharmacological properties, potency
against individual isoforms and selectivity profiles, but also in their
structural requirements for efficient target binding as well as their
mode of inhibition and effects on downstream signalling, it is
likely that the biological activity of different AKT inhibitors will be
significantly influenced by AKT genotype in addition to the overall
genetic background of the target cell. For example, allosteric
inhibitors bind to AKT through interactions with the PH-domain/
kinase-domain interface,12 which is a key feature of the inactive
kinase. ATP-competitive inhibitors, on the other hand, bind to the
active conformation in which the PH domain has swung away
from the kinase domain and expose the ATP-binding pocket.
Therefore, mutations that disrupt drug binding are expected to
target different regions of the molecule depending on which class
of drugs is interrogated. Unfortunately, determinants of context-
specific drug activity are ill-defined, a limitation that complicates
the efficient implementation of AKT-targeting strategies and limits
the therapeutic scope of AKT-targeting agents. To improve our
understanding of genotype/drug activity relationships, we have
carried out extensive in vitro characterisation of several clinical
AKT inhibitors to determine their biochemical and biological
activity in clinically relevant mutant variants of AKT, and used
molecular docking and homology models to understand the
structural basis of these relationships. To explore whether and
how the mode of AKT inhibition could influence the extent of
drug-induced cell killing, we carried out phosphoproteomic
profiling experiments in AKT-dependent cells treated with
allosteric or ATP-competitive AKT inhibitors. Indeed, we found
that drug-class-specific phosphopeptide signatures can be identi-
fied, and that co-targeting kinases involved in the regulation of
these peptides can effectively induce cell death and overcome
acquired AKT inhibitor resistance. Additionally, we have identified
acetate excretion as a functional readout of non-catalytic AKT
function, and show that it can be perturbed by allosteric (but not
ATP-competitive) AKT inhibitors. Our analysis provides insight into
the context-specific activity of clinical AKT inhibitors and offers a
new set of tools to probe and study AKT function.
METHODS
Antibodies and western blot
Antibodies against Vinculin (13901), AKT1 (2938), AKT2 (3063),
pAKT T308 (13038), pAKT S473 (4060), c-PARP (D214) (5625),
pPRAS40 T246 (13175), PRAS40 (8858), pAKT1 S473 (9018), pAKT2
S474 (8599), panAKT (4685), pBAD S136 (4366), BAD (9239), pChk2
T68 (2197), Chk2 (6334), LC3B (3868), GAPDH (5174), pS6 S235/236
(4858) and S6 (2217) were purchased from Cell Signalling. Cell
lysates were prepared using 1× lysis buffer (9803, Cell Signalling)
supplemented with 1% sodium dodecyl sulfate (SDS) (Sigma,
L3771). Following sonication, lysates were quantified using the DC
assay (Bio-Rad, 5000111) and equal amount of protein lysates
were loaded into Tris-Glycine-SDS gels (Bio-Rad, 567-1095).
Proteins were transferred into nitrocellulose membrane (Bio-Rad,
1704271) using the Trans-Blot Turbo Transfer System (Bio-Rad,
1704150) and were detected using Enhanced Chemiluminescence
(ECL, Amersham, RPN2106/Bio-Rad, 1705062). Signal was captured
on film (Amersham Hyper films ECL, 28906836) and developed
using the Xorgaph X4 imaging system. Western blots were
performed at least twice and a representative experiment
is shown.
Cell lines and chemicals
EBC1 cells were obtained from the Japanese Collection of Research
Bioresources Cell Bank. AU-565, HCC1419, H1694, HT29, ZR-75-1, Hs
746T, BT-474 and MDA-MB-361 cells were purchased from ATCC.
EFM-192A cells were purchased from DSMZ. HGC27 cells were
purchased from Cell Lines Service. All commercially procured cell
lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Life Science) media supplemented with foetal bovine
serum. In order to create MK-2206-resistant MDA-MB-361 cells, 125 ×
106 cells were seeded in a Hyper Flasks (Corning) and treated with 2
μM MK-2206 for 3 months with media and drug being refreshed
every other week. Wild-type and AKT1−/−/AKT2−/− (AKT1/2 DKO)
HCT116 or DLD-1 cells (a gift from Bert Volgestein, John Hopkins
University School of Medicine) were maintained in McCoy’s or
RPMI media, respectively. All media were supplemented with 10%
foetal bovine serum (FBS) (Life Science, 10270106), primocin
(Invivogen, ant-pm-2) and normocin (Invivogen, ant-nr-2). Acetate
Colorimetric Assay Kit was purchased from Sigma (MAK086). MK-
2206 2HCl (Selleckchem, S1078), ARQ 751 (ArQule), miransertib
(ArQule), GSK690693 (Cayman, 16891), ipatasertib (MedKoo,
205467), capivasertib (Selleckchem, S8019), AZD0156 (APExBIO,
B7822), KU-57788 (APExBIO, A8315), GSK2334470 (MedChemEx-
press, HY-14981), OSU-T315 (MedChemExpress, HY-18676),
GSK2578215A (Cayman, 14603), apilimod (MedChemExpress, HY-
14644), rapamycin (Selleckchem, S1039) and torin1 (Selleckchem,
S2827) were diluted in dimethyl sulfoxide (DMSO) according to
the manufacturer’s instructions and used at the indicated
concentrations.
Stable cell lines and site-directed mutagenesis
Human pLPCX-AKT1 and pLPCX-AKT2 were created with standard
cloning techniques. Mutant complementary DNAs (cDNAs) were
generated by site-directed mutagenesis using the Quickchange
Lightning Kit (Agilent, 210513-5)) and the primers (Sigma) are
described in Table 1. Stable cell lines expressing specific mutants
of AKT1 or AKT2 were created with virus supernatants prepared
from HEK293T cells transfected with retroviral packaging vectors
(ψ-ampho) and retroviral constructs overexpressing either AKT1,
AKT2 or different mutants. Infected cells were selected using
puromycin 2 μg/mL (Life Science A1113803).
CRISPR-CAS9 gene editing and siRNA transfections
MDA-MB-361 cells were first transduced with a doxycycline-
inducible Cas9 vector. Briefly, virus supernatants were prepared
from HEK293T cells transfected with second-generation packaging
vectors (psPAX and pMD.2) and Edit-R-Inducible Lentiviral
Cas9 Nuclease vector (Horizon Discovery, CAS11229). A stable
line (MDA-MB-361-iCas9) was generated through blasticidin
selection (4 μg/mL). Subsequently, MDA-MB-361-iCas9 cells were
similarly transduced with lentiviral guide RNA constructs targeting
AKT1 (Addgene, 75500) and AKT2 (Addgene, 77506), and stable
expressing lines were subjected to puromycin selection (2 μg/mL).
To induce simultaneous AKT1 and AKT2 deletion in these cells,
doxycycline (2 μg/mL) was added for 7 days prior to downstream
functional assays.
For RNA interference (RNAi) silencing, MDA-MB-361 cells were
transfected with SMARTpool ON-Target plus siRNAs (small
interfering RNAs) targeting AKT1 (L-003000-00-0005) and AKT2
(L-003001-00-0005) or non-targeting siRNAs (D-001810-10-05)
(Dharmacon). In brief, 2.5 × 105 MDA-MB-361 or 1.5 × 105
EBC1 cells were seeded in 12-well plate and at the same time
transfected with siRNAs (17.5 nM each) against AKT1 and AKT2 or
non-targeting (CTR) siRNA in DMEM media containing 10% FBS. At
48 h after transfection, lysates were collected from each experi-
mental condition for western blot analysis and media were
changed to DMEM (5% FBS). Media were collected 48 h later for
acetate measurement.
Viability assays
Cell viability and cell death were assessed using the trypan blue
exclusion method. Briefly 1–2 × 105 cells were seeded in triplicates
into 60 mm plates and allowed to attach overnight. The following
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day, cells were counted again to establish a baseline reading and
treated with different drug concentrations in media containing 5%
foetal bovine serum. Cells were harvested after 4 days of drug
treatment and counted with a ViCell Cell Viability Analyzer
(Beckman). In all figures “cell number (fold change)” refers to
the fold change in the number of viable cells between the start of
drug treatment and the end of the experiment. All growth assays
have been performed a minimum of two times. Shown are results
from one representative experiment. Statistical significance was
performed using either one- or two-way analysis of variance
(GraphPad Prism) and all statistics can be found in Supplementary
Table 1. Symbols n.s., *, **, *** and **** represent values that are
not significant or having a P value ≤ 0.05, 0.01, 0.001 or 0.0001,
respectively.
For CellTiter-Glo (CTG) viability assays, 5 × 103 MDA-MB-361 or
2.5 × 103 EBC1 cells were seeded in 96 wells. Following treatments
with different drug concentrations, CTG (Promega, G7570) was
added and the plates were read in Spectramax I3 reader. The
depicted “normalised survival” is the fold change in cell number
from the start to end of treatments (4 days), and the curves were
created using GraphPad Prism [nonlinear regression, log(inhibitor)
vs. response− variable slope (four parameters)].
Structural modelling
The crystal structure of inhibitor VIII in complex with AKT1 (PDB
entry 3O9612) was prepared using the default setting of the
protein preparation wizard in Maestro release 2017-2 (Schrödinger
release 2017-2: Maestro, Schrödinger, LLC, New York, NY, 2018)
and used for induced fit docking of MK-2206. The default
parameters were applied, except that re-docking was performed
with XP settings.
The miransertib-AKT1 crystal structure (PDB entry 5KCV13) was
employed as a template to create an AKT2 homology model using
MOE 2018.0101.14 Miransertib was included as environment
during model generation and neither the intermediates nor the
final model were refined.
Please refer to the Supplementary Information for references
regarding the PDB entries and detailed methods and references
regarding the MD simulation.
Cell lysis and sample preparation for mass spectrometry
For each treatment condition, five independent biological
replicates were performed. Cells were washed twice with cold
phosphate-buffered saline supplemented with 1 mM Na3VO4 and
1mM NaF, and lysed in 0.5 mL of urea buffer [8 M urea in 20 mM
HEPES (pH 8.0), supplemented with 1 mM Na3VO4, 1 mM NaF, 1
mM Na4P2O7 and 1mM β-glycerophosphate]. Cell lysates were
further homogenised by sonication (three cycles of 10 s on and
10 s off) and insoluble material was removed by centrifugation.
Protein was quantified by the BCI assay. For each replicate, 325 μg
of protein was reduced, alkylated and digested with TLCK-trypsin
(Thermo Fisher Scientific) as previously described.15 The resultant
peptide solutions were desalted with C18-Oasis cartridges (Waters,
Manchester, UK) as indicated by the manufacturer with slight
modifications as previously described.16 Enrichment of phos-
phorylated peptides was performed with TiO2 as previously
described.15,16
Phosphopeptide detection, identification and quantification
Phosphopeptides were resuspended in 12 μL of reconstitution
buffer (20 fmol/µL enolase in 3% acetonitrile, 0.1% trifluoroacetic
acid) and 5.0 µL were loaded onto a liquid chromatography with
tandem mass spectrometry (LC-MS/MS) system consisting of a
Dionex UltiMate 3000 RSLC directly coupled to an Orbitrap Q-
Exactive Plus mass spectrometer (Thermo Fisher Scientific)
through an EasySpray system. LC-MS/MS was performed as
previously described.15 Mascot Daemon 2.5.0 was used to
automate peptide identification from MS data as indicated
before.15 Label-free peptide quantification was performed using
Pescal, an in-house developed software, that constructed
extracted ion chromatograms (XICs) for all identified peptides
across all samples (±7 p.p.m. mass and ±2min retention time
windows) and calculated the peak areas of the generated XICs.15,17
Normalised peak areas of phosphopeptides were used to calculate
fold change and statistical significance between conditions. All
raw data and statistical analysis are presented as Supplementary
Spreadsheet.
Kinase substrate enrichment analysis
Kinase activity was estimated from phosphoproteomics data using
a kinase substrate enrichment analysis (KSEA) approach.15,17
Briefly, phosphorylated peptides were grouped into substrate
groups associated to particular kinases as annotated in the
PhosphoSite database. Z-scores for each kinase were calculated as
(mS−mP) ×m1/2/d, where mS is the log2 of the mean
abundances for each kinase group, mP is the log2 of the mean
abundances of the whole data set, m is the size of each substrate
group and d is the standard deviation of the mean abundances of
the entire data set. Excel software was used to transform Z-scores
into P values. All raw data and statistical analysis are presented as
Supplementary Spreadsheet.
1H-MRS of culture medium
Media from cultured cells (five biological replicates) were analysed
by proton magnetic resonance spectroscopy (1H-MRS). Five
hundred microlitres of culture media and 50 µL of deuterated
water (D2O, Sigma Aldrich) were placed in a NMR tube, and 50 µL
of 0.75% of TSP (sodium 3-(trimethylsilyl)-2,2,3,3-tetradeuteropro-
pionate) in D2O (Sigma Aldrich) was added to the samples for
chemical shift calibration and quantification.
1H-MRS was performed on a Bruker 500 MHz spectrometer
(Bruker Biospin, Ettlingen, Germany). 1H-MRS: 7500 Hz spectral
width, 32 K time domain points, relaxation delay 2.7, 64 scans and
temperature 298 K. The water resonance was suppressed by a
gated irradiation centred on the water frequency. Spectral
processing was carried out using the Bruker Topspin-3 software
package. Spectral assignments were based on literature values.18
Table 1. Mutagenesis primers.
Forward Reverse
AKT1 D323H gccgtagtcattgtgctccagcacctcgg ccgaggtgctggagcacaatgactacggc
AKT1 D292A cttgcacagcccgaaggctgtgatcttaatgtgc gcacattaagatcacagccttcgggctgtgcaag
AKT1 W80A cgatgacagtggtcgcctgcaggcagcgga tccgctgcctgcaggcgaccactgtcatcg
AKT1 Q79K gacagtggtccacttcaggcagcggatga tcatccgctgcctgaagtggaccactgtc
AKT1 M227Q ccgttggcgtactcctggacaaagcagaggcg cgcctctgctttgtccaggagtacgccaacgg
AKT2 W80A ctcgatgactgtggtcgcctgcaggcagcgtatg catacgctgcctgcaggcgaccacagtcatcgag
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Colorimetric quantitation of acetate in cell culture media
Briefly, in a 6-well plate, cells were seeded at 1–2 × 105 cells/well
and treatments added as indicated. Cell culture media were
collected and centrifuged at 13,000 × g for 10 min to remove
insoluble cell debris. Acetate concentrations in the media were
determined using the Acetate Colorimetric Assay Kit (Sigma,
MAK086) according to the manufacturer’s instructions and all
values were normalised using the cell number.
DNA extraction and exome sequencing
Genomic DNA was extracted from parental and MK-2206-resistant
MD-MB-361 cells using Qiagen DNeasy Blood & Tissue Kit (Cat#:
69504) as per the manufacturer’s instructions. Exome library
preparation was done using Illumina Nextera DNA Exome Kit
(Cat#: 20020616) as per the manufacturer’s instructions. Library
underwent quality control on a 4200 Agilent Tapestation. Paired-
end (2 × 150) sequencing was done using a HiSeq 4000 at 50×
coverage. The results have been deposited at the ArrayExpress
database at EMBL-EBI under accession number E-MTAB-8066
(https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8066).
Detection of MK-2206 via LC-MS/MS
MDA-MB-361 cells were seeded at 3 × 106 cells per T75 flask in
triplicate per timepoint and per cell line. Following MK-2206
incubation (2 µM) or DMSO, culturing media were harvested,
whereas cells were trypsinised, counted and lysed to a concentra-
tion of 1 million cells per 100 µL (9803, Cell Signalling). An aliquot
of lysate or cell media were diluted with acetonitrile:water (1:1),
spiked with DMSO and internal standard was added (three
volumes per diluted lysate in acetonitrile). Calibration curves were
prepared as per treated samples by spiking MK-2206 into lysates
or media, respectively, of DMSO-treated cells. All samples were
centrifuged and supernatant diluted 1 in 10 with water prior to
analysis. Samples were analysed by LC-MS/MS using a Waters
(Milford, MA, USA) Acquity I-class plus LC coupled to a Xevo TQ-XS
triple quadrupole mass spectrometer with electrospray ionisation
in positive ion mode. The LC gradient consisted of formic acid
(0.1%) in water (A) and acetonitrile (B) from 10% to 100% B over
4 min on a Kinetex C18 5 cm × 2.1 mm, 1.7 µm UPLC column
(Phenomenex, Macclesfield, UK) at 0.6 mL/min. MK-2206 was
quantified using the multiple reaction monitoring transition
408.24 > 380.09 at collision energy of 24 eV.
RESULTS
Allosteric AKT inhibitors consistently induce more cell death
compared to ATP-competitive inhibitors
Although both allosteric and ATP-competitive AKT inhibitors have
demonstrated strong single-agent growth inhibitory activity in
human cancer cell lines and xenografts, some evidence suggests
that only the latter can induce regressions in AKT1 E17K-driven
tumours in vivo.9 To establish whether ATP-competitive and
allosteric AKT inhibitors differ in their ability to induce cell death,
we measured the cell-killing effects of treatment with two
different ATP-competitive (ipatasertib and GSK690693) and three
different allosteric inhibitors (MK-2206, miransertib and ARQ 751)
of AKT in a panel of cell lines with genetic lesions known to
activate the PI3K/AKT pathway. Our panel included cancer cell
lines with activating PIK3CA mutations, inactivating PTEN muta-
tions, AKT gene amplification or amplification of either ERBB2 or
MET (both of which have been previously shown to be associated
with AKT dependence19,20). Based on our previous studies (PMID:
25551293), we chose a dose of 2 μM MK-2206 as our benchmark,
as this was sufficient to induce robust cell death in MDA-MB-361
cells. We then performed CTG assays in both MDA-MB-361 and
EBC1 cells using a range of doses of GSK690693, ipatasertib,
capivasertib, MK-2206, ARQ 751 and miransertib, and selected
doses that had similar growth-suppressive effects compared to
2 μM MK-2206 (Supplementary Fig. 1A). We found that in all cell
lines tested, allosteric inhibitors (MK-2206, miransertib or ARQ 751)
caused more or equal cell death at lower concentrations
compared to the two ATP-competitive inhibitors (ipatasertib and
GSK690693), despite similar cytostatic activity (Fig. 1a and
Supplementary Fig. 1B). Interestingly, we could not detect any
significant differences in the extent of inhibition of AKT substrates
phosphorylation (PRAS40 and BAD) between ATP-competitive and
allosteric AKT inhibitors at concentrations where the latter induce
more cell death (Fig. 1b and Supplementary Fig. 1C, D). We also
compared the cell-killing effects of ipatasertib and ARQ 751 in
washout experiments using four times higher concentrations of
the former. We found that as little as 30 min of drug exposure
were sufficient to induce significant cell death with ARQ 751, but
not ipatasertib, which did not induce any measurable cell death
during this time (Fig. 1c). To rule out the possibility that the higher
cell-killing activity of allosteric inhibitors was due to off-target
effects, we ectopically expressed AKT1 W80A or AKT2 W80A,
which we and others have previously shown to confer resistance
to MK-2206.19,21 As expected, expression of either mutant in drug-
sensitive MDA-MB-361 cells completely rescued the growth
inhibitory and cell death-inducing effects of MK-2206 (Fig. 1d).
However, to our surprise, cells expressing AKT1 W80A and not
AKT2 W80A remained significantly sensitive to ARQ 751 (Fig. 1d),
suggesting that this mutation does not universally confer
resistance to all allosteric inhibitors, and that its effects on drug
binding can be isoform-specific. Western blot analysis confirmed
that phosphorylation of AKT and AKT substrates, such as PRAS40
and BAD, were sensitive to ARQ 751 treatment and also partially
sensitive to miransertib (Fig. 1e). However, this model did not
allow us to determine whether the observed biochemical
resistance was influenced by the presence of endogenous AKT
isoforms. We therefore expressed each mutant in HCT116 cells
where AKT1 and AKT2 (the only isoforms expressed in these cells)
had been knocked out (hereafter referred to as HCT116 AKT1/2
DKO).22 Again, we found that AKT1 W80A was resistant to
dephosphorylation induced by MK-2206 and to a lesser degree by
miransertib, but remained sensitive to ARQ 751 (Fig. 1f). However,
AKT2 W80A was significantly resistant to all three inhibitors at all
concentrations tested (Fig. 1f). These data suggested that these
clinically relevant allosteric AKT inhibitors differed in their
individual requirements for target binding.
Individual allosteric AKT inhibitors have common and distinct
target binding requirements that influence the nature of
resistance mutations
We next wanted to explore how differences in target binding
requirements of individual allosteric inhibitors could help predict
drug-specific resistance mutations. Due to the absence of an
experimental structure, we generated a docking model of MK-
2206 bound to AKT1 and compared it to the miransertib-AKT1
crystal structure (PDB entry 5KCV13) to determine possible sites of
interaction that were unique to each compound. Our analysis
revealed that the side chain of Trp 80 in the PH domain of AKT1 π-
stacks with MK-2206 (similar to what has been reported for AKT
inhibitor VIII12) (Fig. 2a). This is consistent with the observed
effects of the W80A mutation on AKT1 phosphorylation and cell
survival in response to inhibitor treatment (Fig. 1d–f). In contrast,
miransertib seems to engage less extensively with Trp 80 in AKT1
(Fig. 2b). However, ectopic expression of this mutant in MDA-MB-
361 cells also confers a significant degree of resistance to
miransertib- and ARQ 751-induced cell death (Fig. 1d, right panel)
and causes a right-shift in the biochemical response to these
drugs both in MDA-MB-361 cells and in our HCT116 AKT1/2 DKO
reconstitution model (Fig. 1e, f). To investigate this in more detail,
we have conducted 50 ns MD simulations of AKT1 in complex with
MK-2206 and miransertib. The centre of imidazo(4,5-b)pyridine
ring of miransertib is located further away from the W80 indole
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centroid compared to the centroid of the miransertib tricyclic ring
system (Supplementary Fig. 2B). Whenever miransertib and W80
are in closer proximity, the ring systems partly overlap. This can be
observed, for example, after 22 or 40 ns of simulation, but does
not appear to be stable (Supplementary Fig. 2B, C). Full stacking of
both bicycles onto each other requires pronounced changes to
the miransertib-binding mode (Supplementary Fig. 2D). Consistent
with the static input model, miransertib engages in less stacking
interactions with W80 during the simulation. In contrast, W80
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core throughout the whole course of the simulation and no
changes in the MK-2206-binding mode were observed (Supple-
mentary Fig. 2B, C).
Interestingly, we noticed that the effects of the W80A mutation
on AKT and AKT substrate phosphorylation (PRAS40 and BAD) as
well as on cell survival in response to miransertib and ARQ 751
were significantly less pronounced in AKT1 compared to AKT2. In
fact, ARQ 751 was able to induce cell death in cells expressing
AKT1 W80A, but not AKT2 W80A (Fig. 1d–f). To better understand
the isoform-specific effects of the W80A mutation on inhibitor
response, we created a homology model of miransertib bound to
AKT2 (Fig. 2c) as the chemical structure of ARQ 751 is currently
unavailable. Surprisingly, we found that Trp 80 interacts with
miransertib in a similar manner compared to AKT1. Overall, the
majority of residues in close proximity to miransertib are
conserved, and the two non-conserved residues (Gln 59 and Ser
205 in AKT1 vs. Gln 59 and Thr 207 in AKT2) cannot explain the
observed differences. This suggests that perhaps differences in the
kinetics of the PH-domain and kinase-domain interactions in AKT1
vs. AKT2 could regulate the stability of the interface and therefore
impact drug binding.
We had also included ATP-competitive inhibitors in our
evaluation of W80A mutants as controls. Surprisingly, we have
found that the W80A mutation in AKT2 (but not AKT1) also right-
shifted the response to ipatasertib (Supplementary Fig. 2A). This
was highly unexpected given that the active kinase domain, which
primarily exists in the PH-out conformation, should be positioned
far away from the PH domain where Trp 80 is. However, we
noticed that compared to wild-type AKT2, AKT2 W80A expression
led to a significantly lower level of substrate phosphorylation in
vehicle-treated HCT116 AKT1/2 DKO cells (Fig. 1f), suggesting that
this mutation interferes with the active protein conformation that
is required for both catalytic turnover and inhibitor binding.
Importantly, this is in contrast to AKT1, where substrate
phosphorylation levels do not appear to be affected by the
W80A mutation (Fig. 1f). This further highlights major differences
in these highly conserved isoforms in response to protein
mutation and treatment with a variety of compounds.
Compared to MK-2206, miransertib seems to engage in more
extensive contacts with the kinase domain and a different set of
contacts with the PH domain, including a hydrophobic interaction
with Gln 79 (Fig. 2b, c), a site that has been reported to be
mutated in a small number of human tumours (cbioportal.org). We
therefore predicted that mutation of this site could selectively
confer resistance to miransertib, but not MK-2206. We mutated
Gln 79 to a Lys residue and expressed the mutant cDNA in MDA-
MB-361 (Fig. 2d–f) and HCT116 AKT1/2 DKO cells (Fig. 2g).
Consistent with our prediction, we found that expression of AKT1
Q79K confers biochemical and biological resistance to miransertib
and ARQ 751, but not MK-2206 (Fig. 2d–g). This was evident in
both dose titration (Fig. 2e) and washout (Fig. 2f) experiments.
Given that the binding pocket targeted by all existing allosteric
inhibitors is in the PH-domain/kinase-domain interface, mutational
disruption of the interface should lead to resistance to all allosteric
inhibitors. Indeed, we see that mutation of Asp 323 to His in AKT1,
which has been found to disrupt the interface,23 confers biological
(Fig. 2h) and biochemical (Fig. 2i) resistance to miransertib, ARQ
751 and MK-2206. This protective effect is not observed when a
mutant cDNA that contains both the D323H mutation and a
kinase-inactivating mutation (D292A) is expressed (Fig. 2h–i).
Mutation of the AKT gatekeeper residue “right-shifts” the response
to an ATP-competitive inhibitor, but does not affect response to
others
The active site of protein kinases, including AKT, contains a residue
that partially or fully blocks a hydrophobic region in the ATP-
binding pocket. This residue is referred to as the gatekeeper, and
mutations of this site are the mechanistic basis for resistance to a
number of clinically relevant ATP-competitive inhibitors of
oncogenic kinases. Given the encouraging data from phase 2
clinical trials of capivasertib in AKT mutant cancers, understanding
the impact of mutations on the response to this class of drugs
could be critical in predicting potential mechanisms of acquired
resistance. We therefore mutated the gatekeeper residue Met 227
in AKT1, and assessed its impact on the response to various ATP-
competitive and allosteric AKT inhibitors. We find that mutation of
Met 227 to Gln (M227Q) significantly affected the biochemical and
biological response (in the HCT116 AKT1/2 DKO and MDA-MB-361
cell line models, respectively) to GSK690693, while having no
effect on ipatasertib (Fig. 3a, b). Interestingly, cells were more
sensitive to capivasertib as shown by an increase in cell death and
decreased phosphorylation of PRAS40 and BAD proteins. (Fig. 3a,
b). The crystal structure of AKT2 bound to GSK690693 (PDB entry
3D0E24) shows that this compound extends to an area between
the gatekeeper and the Lys181–Glu200 salt bridge that is
otherwise unoccupied in the capivasertib and ipatasertib struc-
tures (Fig. 3d). This both restricts the available space and creates a
hydrophobic environment around the gatekeeper. To assess the
impact of the M227Q mutation on GSK690693 binding compu-
tationally, we employed the protein design program Osprey
version 2.2 beta25,26 as described previously.27 This program
estimates ligand affinity by calculating a so-called K* score, where
higher values predict tighter binding. Indeed, the results
suggested decreased binding of GSK690693 to the corresponding
AKT2 M229Q mutant (K* scores of 2.97e+59 and 6.9e+52 for wild-
type and M229Q, respectively), but not complete loss due to, for
example, steric incompatibilities (Fig. 3c, left panel), consistent
with the observed right-shift. AKT1 and AKT2 residues within the
Fig. 1 Characterisation of the cell death-inducing effects of various AKT inhibitors and of the W80A mutation on allosteric AKT inhibitor
response. a Allosteric AKT inhibitors have higher cell death-inducing activity compared to ATP-competitive inhibitors. A panel of cancer cell
lines with the various PI3K/AKT-activating lesions (shown in the table on the left) was treated with three allosteric AKT inhibitors (MK-2206,
miransertib and ARQ 751) and two ATP-competitive AKT inhibitors (GSK690693 and ipatasertib) at the indicated doses. The fraction of dead
cells following 4 days of drug treatment is shown (cell death %). b Allosteric and ATP-competitive inhibitors have comparable effects on AKT
kinase inhibition. The effects of AKT inhibitors on AKT and AKT substrate phosphorylation was assessed in MDA-MB-361 cells by immunoblot
using the indicated antibodies following 18 h of treatment. c The cell death-inducing effects of the allosteric AKT inhibitor ARQ 751 and the
ATP-competitive inhibitor ipatasertib were compared in washout experiments. Cells were treated with the indicated doses of drug for either
30min or 1 h. The drug was then removed and cells were extensively washed before allowing them to grow for an additional 72 h. As a
control, cells were also continuously exposed to drug for the duration of the experiment. The fold change in cell numbers (left) and the
fraction of dead cells following 3 days of drug treatment (right) is shown. d The W80A mutation confers resistance to some but not all
allosteric inhibitors in an isoform-selective manner. AKT1 W80A or AKT2 W80A was ectopically expressed in MDA-MB-361 cells. Cells were
treated with MK-2206, miransertib or ARQ 751 at the indicated doses. The fold change in cell numbers (left) and the fraction of dead cells
following 4 days of drug treatment (right) is shown. e Cells were also treated for 18 h and lysed. Lysates were analysed by immunoblot with
the indicated antibodies. f HCT116 AKT1/2 DKO cells were stably transduced with wild-type or W80A variants of either AKT1 or AKT2. Cells
were then treated with the indicated drugs and lysed. Lysates were analysed by immunoblot with the indicated antibodies. n.s., not
significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
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ATP-binding site are highly conserved. However, to ensure that
our modelling scores are not due to an AKT2 effect, we repeated
the analysis with a GSK690693-bound AKT1 homology model and
obtained similar results (K* scores of 1.6e+59 and 5.9e+52 for wild-
type and M227Q, respectively) (Fig. 3c, right panel).
Surprisingly, we found that this gatekeeper mutation also
significantly lowers the sensitivity to the various allosteric
inhibitors tested (MK-2206, ARQ 751 and miransertib) (Fig. 3a, b),
suggesting that the stability or the conformational kinetics of the
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introduction of a polar group at the gatekeeper site that is in close
proximity.
Allosteric and ATP-competitive inhibitors of AKT have distinct
effects on downstream signalling
Given the differential pattern of cell-killing activity between
allosteric and ATP-competitive inhibitors, we reasoned that each
inhibitor class might be associated with distinct effects on
downstream signalling. We therefore treated AKT-dependent
MDA-MB-361 and EBC1 cells with two allosteric (MK-2206 and
ARQ 751) and two ATP-competitive inhibitors (GSK690693 and
ipatasertib) and profiled their effects on the phosphoproteome
using MS (Fig. 4a, b). Drug concentrations were chosen based on
similar potency in suppression of cell proliferation and AKT
substrate phosphorylation in cells. We confirmed target engage-
ment with all inhibitors tested in the phosphoproteome data as
demonstrated by a decrease in the phosphorylation of known AKT



























































































































































































































































































































































































































Fig. 3 The M227Q gatekeeper mutation confers resistance to select ATP-competitive and allosteric AKT inhibitors. a MDA-MB-361 cells
were stably transduced with wild-type AKT1 or AKT1 M227Q. Cells were then treated with the indicated doses of various AKT inhibitors as
shown. The fold change in cell numbers (left) and the fraction of dead cells (right) following 4 days of drug treatment is shown. b HCT116
AKT1/2 DKO cells stably transduced with either wild-type AKT1 or AKT1 M227Q were treated with the indicated doses of various AKT
inhibitors as shown. Cells were lysed following treatment and analysed by western blot with the indicated antibodies. c Crystal structure of
AKT2 bound to GSK690693 (left) and a homology model of AKT1 bound to GSK690693 (right). The proteins in the wild-type models are
depicted in magenta (left side, AKT2 crystal structure) and dark green (right side, AKT1 homology model), whereas GSK690693 is shown in
blue. In the mutant models, the compound and mutant residue conformations are coloured yellow (left side) and rose and grey (right side,
please note that two different M227Q side chain rotamers are included), respectively. d Alignment of the crystal structures of GSK690693
(magenta, PDB entry 3D0E, in complex with AKT2), ipatasertib (light blue, PDB entry 4EKL, in complex with AKT1) and capivasertib (dark blue,
PDB entry 4GV1, in complex with AKT1). GSK690693 extends to an area between the gatekeeper M229 (orange sticks) and the K181–E200 salt
bridge (orange sticks), which is not occupied by ipatasertib and capivasertib. We have highlighted the part of GSK690693 that extends into
this area with dotted lines. The protein in all three complexes is depicted as grey cartoon. n.s., not significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
and ****P ≤ 0.0001.
Fig. 2 Mutations in both the kinase and PH domains of AKT can cause drug-specific allosteric AKT inhibitor resistance. a A docking model
of MK-2206 bound to AKT1. b Crystal structure of AKT1 bound to miransertib. c A homology model of AKT2 bound to miransertib. d, e Effects
of the Q79K mutation on the response to AKT inhibitors. dMDA-MB-361 cells were stably transduced with wild-type AKT1 or AKT1 Q79K. Cells
were then treated with the indicated doses of MK-2206, ARQ 751, miransertib, GSK690693, ipatasertib or capivasertib. The fold change in cell
numbers (top) and the fraction of dead cells (bottom) following 3 days of drug treatment is shown. e MDA-MB-361 cells expressing either
AKT1 or the Q79K mutant were treated with increasing doses of MK-2206 or miransertib. The fold change in cell numbers (left) and the
fraction of dead cells (right) following 3 days of drug treatment is shown. f The effects of the AKT1 Q79K mutation in response to MK-2206 and
miransertib was evaluated in washout experiments. MDA-MB-361 cells stably expressing wild-type AKT1 or AKT1 Q79K were treated with the
indicated doses of drug for either 1 h or continuously for 72 h. The fold change in cell numbers and the fraction of dead cells (bottom) at 72 h
is shown. g HCT116 AKT1/2 DKO cells were stably transduced with wild-type AKT1 or AKT1 Q79K. Cells were subjected to western blot
analysis, following o/n drug treatment, with the indicated antibodies. h A mutation that disrupts the kinase-domain/PH-domain interface
confers resistance to all allosteric inhibitors. MDA-MB-361 cells were stably transduced with wild-type AKT1 or the mutant variants D323H,
D292A (a kinase-deficient mutant), and the double mutant D323H-D292A. Cells were treated with allosteric AKT inhibitors as shown. The fold
change in cell numbers and the fraction of dead cells following 4 days of drug treatment is shown (cell death %). i HCT116 AKT1/2 DKO cells
were stably reconstituted with the indicated AKT variants and treated o/n with allosteric AKT inhibitors as shown. Cells were then lysed and
analysed by immunoblot with the indicated antibodies. n.s., not significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
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an increase or a decrease in AKT phosphorylation in samples that
were treated with ATP-competitive or allosteric AKT inhibitors,
respectively (Fig. 4a). On western blots, we observed a decrease in
the phosphorylation of the AKT substrate PRAS40 following
treatment with all four inhibitors (Fig. 4c). Consistent with known
mechanisms of action, we also detected either an increase or a
decrease in the phosphorylation of AKT following treatment with
ATP-competitive or allosteric inhibitors, respectively (Fig. 4c). We
found identical results when we quantified our MS data, including
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Fig. 4 Phosphoproteomic signatures of AKT inhibitors uncover potential therapeutic co-targets. a MDA-MB-361 and EBC1 cells were
treated with the indicated drugs for 6 h and lysed. Lysates were subjected to phosphopeptide enrichment, and analysed by quantitative LC-
MS/MS. Shown are the quantification of mass spectra corresponding to known AKT substrates. b Phosphoproteomic data was analysed by
kinase substrate enrichment analysis (KSEA). Shown are all kinases predicted to be associated with the observed phosphopeptide signatures,
that were affected differently by each inhibitor class (i.e. ATP-competitive vs allosteric) but similarly by both inhibitors of the same class in at
least one of the cell lines. c Lysates from a, b were also subjected to immunoblot to further document drug activity using the indicated
antibodies. d–g MDA-MB-361 cells were treated with various AKT inhibitors either alone or in combination with the ATM inhibitor AZD0156
(d), the DNA-PK inhibitor KU-57788 (e), the PDK1 inhibitor GSK2334470 (f), or the ILK inhibitor OSU-T315 (g). h, i MDA-MB-361 cells were also
treated with various AKT inhibitors either alone or in combination with the PIKFYVE inhibitor apilimod (h), or the mTORC inhibitors rapamycin
or torin1 (i) at the indicated doses. The fold change in cell number and fraction of dead cells following 4 days of drug treatment is shown (cell
death %). n.s., not significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
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previously been difficult to observe in MS experiments (Fig. 4a). To
identify effector kinases whose function might be selectively
altered by one class of AKT inhibitors, we carried out KSEA and
asked whether treatment with both the allosteric inhibitors or
both the ATP-competitive inhibitors were associated with a
significant enrichment (positive or negative) of any kinase
signatures. We identified seven potential kinases (PDK1, ATM,
TBK1, PIKFYVE, LRRK2, DNA-PK, ILK) whose activity was differen-
tially affected by active-site AKT inhibitors vs. allosteric inhibitors
in both cell lines tested (Fig. 4b). We hypothesised that these
kinases could represent signalling intermediates in survival
pathways that were regulated by aspects of AKT function
differentially targeted by each inhibitor class. To assess whether
inhibition of any of these kinases impaired or enhanced the cell-
killing activity of AKT inhibitors, we combined inhibitors of each
kinase with either ATP-competitive or allosteric inhibitors of AKT.
We excluded the use of TBK1 inhibitors because currently
available compounds are not sufficiently selective.28,29 We chose
to use lower concentrations of AKT inhibitors than we had used
previously to both minimise the potentially additive off-target
effects of the drug combinations, and to maximise the probability
of seeing enhancing effects. First, we examined the effects of ATM
and DNA-PK inhibitors because both of these kinases are
regulators of the DNA damage response and AKT has previously
been shown to promote DNA repair and checkpoint activation.30
We found that the ATM inhibitor AZD0156 (Fig. 4d) or the DNA-PK
inhibitor KU-57788 (Fig. 4e) potentiated the cell death-inducing
effect of AKT inhibitors in MDA-MB-361 cells (and to a lesser
degree in EBC1 cells; Supplementary Fig. 3A), despite having no
detectable effects as single agents. The biochemical activity of the
various compounds was documented via western blot by
assessing phosphorylation of relevant substrates and downstream
effectors (Supplementary Fig. 3B). Although the magnitude of the
effect was variable, we observed a similar pattern of cell killing
when we tested these combinations in one additional PIK3CA-
mutant breast cancer cell line, namely BT-474 (Supplementary
Fig. 3C). Next, we looked at the effects of combining AKT inhibitors
with inhibitors of either PDK1 or ILK. PDK1 phosphorylation of AKT
is necessary for its activation and has been shown to be involved
in negative feedback regulation of PI3K signalling.31 Therefore, it is
possible that its activation could mitigate the effects of AKT
inhibitors. ILK, on the other hand, has been shown to directly
modulate AKT activity.32 Indeed, we found that the combination
of the PDK1 inhibitor GSK2334470 (Fig. 4f) or the ILK inhibitor
OSU-T315 (Fig. 4g) with AKT inhibitors of either class potentiated
cell death in all cell lines tested (Fig. 4f, g and Supplementary
Fig. 4A–C), including MK-2206-resistant cells. We also assessed the
effects of the LRRK2 inhibitor GSK2578215A in combination with
either MK-2206 or ipatasertib, and found that this compound did
not alter the response to AKT inhibitors and did not have any
single-agent activity in either MDA-MB-361 or BT-474 cells
(Supplementary Fig. 4D, E). Finally, we examined the effects of
combining AKT inhibitors with the PIKFYVE inhibitor apilimod and
found that it significantly blunted the cell-killing effect of allosteric
AKT inhibitors in all cell lines tested, but only modestly altered the
effects of ATP-competitive inhibitors (Fig. 4h, Supplementary
Figs. 3C, 5A). PIKFYVE is a PI5 kinase that regulates lysosomal
function. Inhibition of PIKFYVE has been shown to block
autophagy by impairing lysosomal maturation.33 Therefore, our
data suggest that the cell-killing activity of AKT inhibitors might
require functional autophagic flux. Consistently, we see induction
of the autophagic marker LC3B in MDA-MB-361 cells treated with
MK-2206, but not GSK690693 (Supplementary Fig. 5B). We
therefore hypothesised that the pharmacological induction of
autophagy would facilitate AKT inhibitor-induced cell killing. Given
that mammalian target of rapamycin (mTOR) is a critical cellular
inhibitor of autophagy, we decided to combine a variety of ATP-
competitive or allosteric AKT inhibitors with inhibitors of mTOR.
Indeed, we found that the combination of AKT inhibitors with
either rapamycin or torin1 significantly potentiated the cell-killing
activity of five different AKT inhibitors in MDA-MB-361 cells (Fig. 4i
and Supplementary Fig. 6).
Acquired resistance to MK-2206 can be driven by mechanisms
that do not involve AKT mutation, but confer biochemical
resistance to the drug
In order to model acquired resistance to an allosteric AKT inhibitor,
we exposed MDA-MB-361 cells to a high dose of MK-2206. Drug
treatment led to significant cell death with only a small fraction of
cells surviving after 12 weeks of treatment. Surviving cells were
expanded in the presence of drug for an additional 2 weeks.
Western blot analysis showed that phosphorylation of AKT and
two of its substrates (PRAS40, BAD) were unaffected by MK-2206
in the resistant subline (Fig. 5a, e). To assess whether the
resistance phenotype was stable, we cultured the resistant
population for 4 weeks in the absence of drug (Res −) and then
re-challenge with MK-2206. Cells remained drug resistant follow-
ing this 4-week drug holiday, suggesting that the phenotype was
indeed stable (Fig. 5b).
In order to examine whether AKT remained a relevant
therapeutic target in these cells, we evaluated the response of
MK-2206-resistant cells to additional allosteric and ATP-
competitive AKT inhibitors (Fig. 5c, d). We find that resistant cells
remained sensitive to both ipatasertib and GSK690693. Interest-
ingly, these cells also showed a blunted response to both
miransertib and ARQ 751 (Fig. 5d).
We also assessed the effects of MK-2206, ARQ 751 and
miransertib on the phosphorylation of total AKT, AKT1 or AKT2,
as well as on phosphorylation of the AKT substrates PRAS40 and
BAD, in both parental and MK-2206-resistant MDA-MB-361 cells
(Fig. 5e). We found that compared to parental cells, drug-resistant
cells showed no changes in phosphorylation of total AKT (on both
T308 and S473) or AKT1 in response to MK-2206, and showed no
evidence of AKT2 phosphorylation in the presence or absence of
drug (Fig. 5e). Consistently, MK-2206 treatment had little to no
effect on the phosphorylation of PRAS40 or BAD in MK-2206-
resistant cells, compared to parental controls (Fig. 5e). We also
found that phosphorylation of total AKT and AKT1 was
significantly (but not completely) resistant to miransertib treat-
ment, as was phosphorylation of both PRAS40 and BAD.
Furthermore, we found that compared to parental cells, AKT
phosphorylation was only slightly protected (most clearly seen on
total pAKT S473) from ARQ 751 treatment in MK-2206-resistant
cells and only at the lowest doses, and AKT substrate (PRAS40 and
BAD) phosphorylation remained highly sensitive to this com-
pound (Fig. 5e). Given these results and our functional mutational
analysis, we hypothesised that the mechanism of resistance could
involve the acquisition of an AKT1 mutation. We therefore carried
out whole-exome sequencing in our parental and MK-2206-
resistant cells. To our surprise, we could not detect any changes in
the coding sequences of either AKT1 or AKT2 in MK-2206-resistant
cells, suggesting that biochemical protection from drug-induced
dephosphorylation does not occur as a consequence of AKT
mutation. Next, we examined intracellular MK-2206 drug concen-
trations following 1 or 6 h of drug exposure and found that
resistant cells showed lower drug accumulation, suggesting that
drug efflux could contribute to the observed biochemical
resistance (Supplementary Fig. 7).
Finally, given that rapamycin is a clinically approved drug,
and that our data demonstrate enhanced cell death when
combining rapamycin with AKT inhibitors, we wanted to know
whether acquired resistance to MK-2206 could be overcome
with this particular drug combination. Indeed, we found that
although MK-2206-resistant cells remain largely resistant to the
MK-2206/rapamycin combination, treatment with ARQ 751,
miransertib, GSK690693 or ipatasertib in combination with
A systematic molecular and pharmacologic evaluation of AKT inhibitors. . .
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rapamycin did induce significant cell death in drug-resistant
cells (Fig. 5f).
Acetate excretion is a functional readout of non-catalytic AKT
function, and can be perturbed by allosteric AKT inhibitors
Our data suggest that allosteric AKT inhibitors can target aspects
of AKT function that cannot be effectively inhibited by ATP-
competitive compounds. Furthermore, we have previously shown
that AKT can signal through non-catalytic functions,19 but
biomarkers of kinase-independent function have not yet been
identified. We hypothesised that allosteric AKT inhibitors could be
better suppressors of non-catalytic function compared to ATP-
competitive inhibitors, and set out to identify biomarkers of these
kinase-independent functions. Given that AKT-dependent phos-
phorylation cannot explain certain aspects of AKT-dependent
cellular metabolism,34 we decided to explore the potential
involvement of non-catalytic AKT function in regulating metabo-
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Fig. 5 Acquired biological resistance to MK-2206 is associated with biochemical AKT1 resistance that is not mediated by AKT mutation.
a MDA-MB-361 cells were chronically treated with 2 μM MK-2206 for 12 weeks. Surviving cells were removed from treatment and re-
challenged with the indicated drugs for 18 h. Cells were lysed and lysates examined by immunoblot with the indicated antibodies. b Parental
and MK-2206- resistant MDA-MB-361 cells cultured in MK-2206 (Res +) or not (Res −) were treated with the indicated doses of MK-2206. The
fold change in cell numbers (left) and the fraction of dead cells (right) following 4 days of drug treatment is shown. c Parental and MK-2206-
resistant MDA-MB-361 cells were treated with the indicated doses of ATP-competitive and allosteric AKT inhibitors. The fraction of dead cells
following 4 days of drug treatment is shown (cell death %). d Parental and MK-2206-resistant MDA-MB-361 cells were treated with the
indicated doses of various allosteric AKT inhibitors. The fold change in cell numbers (left) and the fraction of dead cells (right) following 4 days
of drug treatment is shown. e Cells treated as in d were also lysed following 24 h of drug treatment, and lysates were examined by western
blot using the indicated antibodies. f MDA-MB-361 cells were treated with various AKT inhibitors either alone or in combination 50 nM
rapamycin. The fold change in cell numbers (top) and the fraction of dead cells (bottom) following 4 days of drug treatment is shown. n.s., not
significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
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concentration of 16 different metabolites in cell culture media
from AKT-deficient and AKT-reconstituted cells. Of these, four
metabolites (lactate, glucose, formate and acetate) showed a
significant change following AKT reconstitution. Of these four,
acetate had the greatest fold change and the highest statistical
significance. Therefore, we decided to focus on acetate for our
follow-up work. Our results showed that excretion of acetate was
significantly decreased when AKT2 expression was reconstituted
through retroviral transduction of AKT1/2-deficient HCT116 (DKO)
cells (Supplementary Table 2). A similar decrease was observed
using a commercially available acetate detection Colourimetric
Assay Kit (Fig. 6a). We also asked whether this effect required AKT
catalytic function, and found that the decrease in acetate
excretion could be induced through expression of either wild-
type kinase-competent AKT2 or a kinase-deficient AKT2 mutant
(AKT2 K181M) in AKT1/2 DKO HCT116 cells. Unless, AKT2 K181M is
able to retain some level of kinase activity that is below our level
of detection, these data suggest that this function of AKT does not
require catalytic activity (Fig. 6a). To confirm our results, we
simultaneously knocked down AKT1 and AKT2 in MDA-MB-361 or
EBC1 through either RNAi or CRISPR (clustered regularly inter-
spaced short palindromic repeats), and we found a significant
increase in acetate excretion following AKT knockdown (Supple-
mentary Fig. 8A, B). We also examined AKT1/2 DKO HCT116 or
DLD-1 cells and found that, compared to their AKT-proficient
parental counterparts, acetate excretion was increased (Supple-
mentary Fig. 8C). We then asked whether the observed decrease
in acetate excretion could be reversed by AKT inhibitors. Indeed,
we found that the decrease in acetate excretion could be reversed
by treatment with MK-2206 in cells that expressed wild-type AKT2,
but not the MK-2206-resistant AKT2 W80A mutant (Fig. 6b). We
then assessed the effects of AKT inhibitors on acetate excretion in
MDA-MB-361 and EBC1 cells (Fig. 6c, d). We found that three
different allosteric AKT inhibitors were significantly more efficient
at inducing acetate excretion compared to three different ATP-
competitive inhibitors. In fact, no increase in acetate excretion
could be detected in EBC1 cells treated with GSK690693
compared with MK-2206. We also found that ectopic expression
of AKT1 Q79K in MDA-MB-361 cells significantly impaired
miransertib- and ARQ 751-induced acetate excretion compared
to cells ectopically expressing wild-type AKT1 (Fig. 6e), suggesting
that the drug effect on acetate excretion was indeed due to
inhibition of AKT. These data strongly suggest that acetate
excretion can be regulated by a kinase-independent function of
AKT that is highly sensitive to allosteric AKT inhibitors, but virtually
insensitive to ATP-competitive inhibitors. Finally, we wanted to
know whether acquired resistance to MK-2206 had an impact on
drug-induced acetate excretion. Indeed, we found that in MK-
2206-resistant MDA-MB-361 cells, MK-2206-induced acetate excre-
tion was severely impaired (Fig. 6f). Furthermore, acetate excretion
after treatment with ARQ 751 was only partially impaired, while
the impairment was more pronounced following treatment with
miransertib, mirroring the cell-killing effects of these compounds
in MK-2206-resistant cells (Figs. 6f, 5d).

















































































































































































































































































































































Fig. 6 AKT regulates acetate excretion independent of kinase activity. a Conditioned media from HCT116 AKT1/2 DKO cells stably
transduced with either wild-type (AKT2) or kinase-dead AKT2 (AKT2 K181M) was collected for acetate quantification. Acetate was quantified
using a colorimetric assay (left). Expression of AKT2 was confirmed by western blot (right). b HCT116 AKT1/2 DKO cell stably transduced with
wild-type (AKT2) or MK-2206-resistant AKT2 (AKT2 W80A) were cultured for 24 h in the presence or absence of MK-2206 as indicated. Culture
media was collected following treatment and acetate levels were assessed with a colorimetric assay. c MDA-MB-361 and EBC1 cells were
cultured for 24 h in the presence or absence of MK-2206 or GSK690693 as indicated. Culture media was collected following treatment
and acetate levels were assessed with a colorimetric assay. d MDA-MB-361 cells were cultured for 24 h in the presence or absence of three
allosteric (MK-2206, ARQ 751 and miransertib) or three ATP-competitive (GSK690693, ipatasertib and capivasertib) AKT inhibitors. Culture
media was collected following treatment and acetate levels were assessed with a colourimetric assay. e MDA-MB-361 cells stably transduced
with either wild-type AKT1 or AKT1 Q79K were cultured for 24 h in the presence or absence of MK-2206, ARQ 751, miransertib, GSK690693, or
ipatasetrtib as indicated. Culture media was collected following treatment and acetate levels were assessed with a colourimetric assay.
f Parental or MK-2206-resistant MDA-MB-361 were cultured for 24 h in the presence or absence of the indicated drugs. Culture
media was collected and acetate levels were assessed with a colorimetric assay. n.s., not significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and
****P ≤ 0.0001.
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DISCUSSION
Recent encouraging data from biomarker-driven clinical trials of
AKT inhibitors have re-boosted enthusiasm about the clinical
utility of these compounds as single agents, and more generally,
about AKT as a therapeutic target in oncology. Despite these
emerging signs of clinical activity, the rarity of the genotype that
defines the sensitive patient population remains at odds with the
much broader pre-clinical therapeutic effects reported for many
AKT-targeting agents that have subsequently failed in the clinic.
This discrepancy is likely due to a number of different factors
including the poor predictive value of some pre-clinical models,
the complexity of the PI3K pathway and the impact that co-
occurring mutations of several pathway components may have on
response to inhibition of a single node, as well as the differences
in the pharmacological requirements that define the anti-tumour
activity of individual AKT inhibitors. Given the rich repertoire of
AKT inhibitors in clinical development, we carried out a systematic
study of the most advanced compounds to better understand and
define the context of their anti-tumour activity.
Our work shows that in cell lines with active wild-type AKT,
allosteric inhibitors are more potent inducers of cell death
compared to ATP-competitive inhibitors, particularly in washout
experiments wherein cancer cells are not continuously exposed to
these drugs. This is an important pharmacological distinction
because, in humans, exposure of tumours to peak biologically
active drug concentrations is generally transient, suggesting that
ATP-competitive inhibitors may not satisfy the pharmacokinetic
requirements for meaningful target engagement. It also warrants
more careful interrogation of intermittent dosing schedules using
high-dose allosteric inhibitors in AKT-active tumours.
We have also found that mutations that confer resistance to
one allosteric inhibitor do not always confer resistance to other
allosteric inhibitors. In one case, we found that a clinically relevant
activating AKT1 mutation,35,36 Q79K, confers resistance to
miransertib, but not MK-2206, further highlighting the impor-
tance of understanding AKT genotype in order to select the
appropriate targeting agent. Similarly, specific mutations can
selectively confer resistance to some but not all ATP-competitive
inhibitors. Of note, we found that the ability of some of these
mutations to confer resistance depends on whether they target a
specific AKT isoform. Given that the allosteric-binding site is held
in place by inter-domain interactions between the PH and kinase
domains of AKT, our data suggest that the nature of these
interactions may be sufficiently different between individual AKT
isoforms to modulate drug binding and possibly basal activity. It
also suggests that the conformation kinetics of the interface
might be critical in allowing drug access, and that mutations that
alter this feature could also confer resistance or enhance
sensitivity.
Consistent with the difference in cell death-inducing potency,
we found, through phosphoproteomic profiling, that allosteric and
ATP-competitive inhibitors can have distinct effects on signal
transduction. This provides evidence that each compound class
may differentially target different aspects of AKT function or have
different effects on feedback regulation. Furthermore, we provide
evidence that these phosphopeptide signatures can be used to
identify kinase drug targets whose inhibition can effectively
induce cell death when combined with AKT inhibitors, even in
cells with acquired AKT inhibitor resistance. Interestingly, these
potentiated effects were observed with both classes of AKT
inhibitors, despite the fact that allosteric inhibitors suppressed,
and ATP-competitive inhibitors increased the phosphorylation
output of these kinases. These data suggest that allosteric
inhibitors may partially block some of the downstream effector
kinases of AKT that are important for AKT-dependent survival,
while ATP-competitive inhibitors may cause their activation
possibly through feedback relief. Importantly, we have also
identified acetate excretion as a functional readout of AKT
function that is independent of kinase activity and that is
significantly more sensitive to allosteric AKT inhibitors. Given the
role of non-catalytic AKT function in cancer cell survival,19 the
incorporation of this type of readout in assay cascades for the
discovery or optimisation of new AKT inhibitors could prove
critical in improving the therapeutic potential of AKT-targeting
agents.
Finally, we have identified a previously unknown mechanism
of AKT inhibitor resistance, which involves biochemical protec-
tion of the primary drug target (AKT1 or AKT2 in this case)
through a non-mutational event. This is an important develop-
ment in our understanding of kinase inhibitor resistance
mechanisms because it suggests that although the primary
drug target remains relevant, its inactivation may require
inhibition of another molecule, which could directly or indirectly
impair drug binding. Our measurements of intracellular MK-2206
concentration in parental and resistant cells suggest that the
observed biochemical resistance could be, at least partly, due to
the activation of a drug efflux pump. However, the fact that the
induced effect of combining MK-2206 with either GSK2334470
or OSU-T315 was partially retained (Supplementary Fig. 4C)
suggests that some free MK-2206 can be accumulated in
these cells.
Our work shows the importance of defining, in molecular detail,
the mechanism of action of individual AKT inhibitors to under-
stand their distinct biological effects. More broadly, it demon-
strates the power of robust comparative pharmacology studies in
determining the most favourable context for the use of specific
therapeutic inhibitors with a shared primary target, and it
highlights the benefits of pharmacological diversity.
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